Q: Hello Team
Is there any red flags with the options the management keep issuing to themselves.
Thank You
Is there any red flags with the options the management keep issuing to themselves.
Thank You
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Hello Peter & Team,
I would be interested in your thoughts on the recent PHM acquisition?
Thank you for the great service.
Tim
I would be interested in your thoughts on the recent PHM acquisition?
Thank you for the great service.
Tim
Q: This stock has lost a quarter of its value since April 20. I realize there was a financing issue, but the steady downward momentum seems to be accelerating. I know growth stocks are volatile, but 25% is a serious fall with no end in sight. Last night on BNN Eric Nuttall described PHM is wildly overpriced and likely to take a huge fall if there is a market correction. Is it time to jump ship?
Q: Good Afternoon,
I just listened to the conference call from the end of April. Correct me if I'm wrong but I think I heard them say that a realistic longer term goal is now $1Bill in annual revenue? Not sure if I misheard them but they also said their EBITDA margin currently is around 60-65%? And companies like this could trade for 10-13x EBITDA? Thank-you
I just listened to the conference call from the end of April. Correct me if I'm wrong but I think I heard them say that a realistic longer term goal is now $1Bill in annual revenue? Not sure if I misheard them but they also said their EBITDA margin currently is around 60-65%? And companies like this could trade for 10-13x EBITDA? Thank-you
Q: Hi Peter & team, PHM halted....do you have any info?
Thank you.
Thank you.
Q: Hi Peter and team
With recent news from the company and no questions asked since Dec. 2013, what is your current view of it?
Gerry
With recent news from the company and no questions asked since Dec. 2013, what is your current view of it?
Gerry
Q: Which Health stock is better buy VRX or CXR. I would hold for 2 to 3 years
Q: POZEN Inc. announced today that they have purchased Tribute Pharmaceuticals and will create a new Company (Aralez Pharmaceuticals) that will trade on both the TSX and NASDAQ. Both stocks are up nicely today and Aralex appears to be well capitalized with additional capital being invested in Aralez.
I own some Tribute and have a few questions:
1. Do you have an opinion on the transaction?
2. Would you think investors in Tribute should sell now or wait and hold shares in the Aralez?
3. What would your thoughts be on buying more shares in Tribute or taking a position in POZEN Inc.
Don
I own some Tribute and have a few questions:
1. Do you have an opinion on the transaction?
2. Would you think investors in Tribute should sell now or wait and hold shares in the Aralez?
3. What would your thoughts be on buying more shares in Tribute or taking a position in POZEN Inc.
Don
Q: Can you please comment on the takeover Of TRX by Pozen and what would you recommend to do with TRX shares. Thanks
Q: I presently hold Concordia, PHM, Walgreen and CVS. In an attempt to increase the health care portion of my portfolio to roughly ten percent I am contemplating purchasing UNH ( United Healthcare) Appreciating you don't really cover US Stocks would I be better off simply adding to my CVS. Is there an overlap here between CVS and UNH and possibly WBA?
Thanks
Thanks
Q: Peter, there is some current speculation regarding US health care stocks and this US Supreme Court Ruling which will apparently happen this month which could throw a monkey wrench into the health care momentum. IE. King Versus Burwell. Could you comment on the potential impact this decision might have on health care stocks generally and patient home monitoring specifically.
Q: Please give your opinion on the GUD announcement today.
Q: I hold BNS and RY in my TFSA, both with large unrealized capital gains. I'm considering selling both and buying a Health Care ETF. If you consider this a good switch, what ETF would you recommend?
Q: Any thoughts on Profound which is expected to trade on June 8? Knight has invested and Goodman will be on the BOD. I know you generally like to wait and see where things settle down
Thanks
Thanks
Q: Following up on a March enquiry re. ENL - would it be better to sell the TSX listing (which, as suggested, has, at times, little or no volume) and buy the NY listing? Or will Toronto simply follow what the US does in terms of valuation?
Clearly ENL has done very well over the last months so certainly want to hold onto it.
Clearly ENL has done very well over the last months so certainly want to hold onto it.
Q: Would appreciate your comments on the Merus Labs update on the review of the German Federal Joint Committee (the "G-BA") related to Emselex® (Darifenacin). A hearing is now scheduled for June 9, 2015, however, the Company anticipates that a final determination of a possible maximum reimbursement price and the specific products which will be included in the proposed class, will likely not occur during the Company's current fiscal year.
Do you think a timing for ruling until next year will create an overhang on the stock and as such hold back it's price appreciation?
Do you think a timing for ruling until next year will create an overhang on the stock and as such hold back it's price appreciation?
Q: Yesterday on BNN you said that GUD was probably #3 in Canadian medical - who is #1 & #2.
Thank you as always.
Thank you as always.
Q: Hello Team
As you know the FDA has granted Fast Track designation to Intellipharmaceuticals abuse deterrent Oxycodone ( Rexistra ). In a nutshell what are the next steps the company would take to get their product to market such as licensing, selling rights, getting production set up etc? How does it all work? Does Intellipharmaceuticals have the financial might to accomplish the task or will they need help? What is a typical time frame between approval and marketing for a product such as this. Considering the issues around the abuse of Oxycondin I expect that Intellipharmaceutis have a good product and opportunity.
Have a Good weekend
Thanks for your help
Clarence
As you know the FDA has granted Fast Track designation to Intellipharmaceuticals abuse deterrent Oxycodone ( Rexistra ). In a nutshell what are the next steps the company would take to get their product to market such as licensing, selling rights, getting production set up etc? How does it all work? Does Intellipharmaceuticals have the financial might to accomplish the task or will they need help? What is a typical time frame between approval and marketing for a product such as this. Considering the issues around the abuse of Oxycondin I expect that Intellipharmaceutis have a good product and opportunity.
Have a Good weekend
Thanks for your help
Clarence
Q: I have recently moved back into the health care sector with half positions in CRH, CXR and NHC. I'm looking to add to my holdings. How would you rank these three names as well as PHM (or any others).
Thanks for your great service.
Dennis
Thanks for your great service.
Dennis
Q: Hi,
Thanks for suggestion that VRX would be a good candidate for a covered call. I bought 100 shares around $270 in early May and wrote a July $300 call for about $1,500. (Un)fortunately, the stock rose quite a lot so now option is in money. Any suggestions what to do? (i.e., do you like VRX enough to suggest I should buy option at a loss so my position isn't exercised?). Thanks for great service!
Thanks for suggestion that VRX would be a good candidate for a covered call. I bought 100 shares around $270 in early May and wrote a July $300 call for about $1,500. (Un)fortunately, the stock rose quite a lot so now option is in money. Any suggestions what to do? (i.e., do you like VRX enough to suggest I should buy option at a loss so my position isn't exercised?). Thanks for great service!